mk-0524 has been researched along with Asthma* in 1 studies
1 trial(s) available for mk-0524 and Asthma
Article | Year |
---|---|
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Prostaglandin D(2) is a proinflammatory mediator believed to be important in asthma and allergic rhinitis (AR). Allelic variants in the prostaglandin D(2) receptor type 1 (DP1) gene (PTGDR) have been suggested to be associated with asthma susceptibility.. We sought to investigate the efficacy of the DP1 antagonist laropiprant (alone or with montelukast) in asthma and seasonal AR and explore whether sequence variations in PTGDR are associated with asthma severity.. For asthma, in a double-blind crossover study, 100 patients with persistent asthma were randomized to placebo or laropiprant, 300 mg/d for 3 weeks, followed by addition of montelukast, 10 mg/d for 2 weeks. PTGDR promoter haplotypes were categorized as high, medium, or low transcriptional efficiency. The primary efficacy end point was FEV(1). For AR, in a double-blind parallel-group study, 767 patients sensitized to a regionally prevalent fall allergen with symptomatic fall rhinitis were allocated to laropiprant, 25 mg/d or 100 mg/d; cetirizine, 10mg/d; or placebo for 2 weeks. The primary end point was the Daytime Nasal Symptoms Score.. For asthma, no significant differences in FEV(1) or asthma symptoms were noted for laropiprant versus placebo or laropiprant plus montelukast vs montelukast (differences between montelukast and placebo: P Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Indoles; Male; Middle Aged; Promoter Regions, Genetic; Quinolines; Receptors, Prostaglandin; Rhinitis, Allergic, Seasonal; Sulfides; Young Adult | 2009 |